Low incidence of vascular complications in patients with diabetes mellitus associated with liver cirrhosis as compared with type 2 diabetes mellitus

Tohoku Journal of Experimental Medicine

Volumn 205, Issue 4, 2005, Pages 327-334

  Fujiwara, Fumikado ^a   Ishi, Mototsugu ^a   Taneichi, Haruhito ^a   Miura, Masanori ^a   Toshihiro, Makiko ^a   Takebe, Noriko ^a   Ishida, Wataru ^a   Kaneko, Yoshihito ^a   Kato, Akinobu ^a   Suzuki, Kazuyuki ^a   Satoh, Jo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Cerebrovascular disease; Diabetic retinopathy; Lipoprotein (a); Liver cirrhosis; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIFIBRINOLYTIC AGENT; APOLIPOPROTEIN; CHOLESTEROL; COMPLEMENTARY DNA; GLUCOSE; HEMOGLOBIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHAQUALONE; PLASMINOGEN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL;

ADULT; AGED; AGING; AMINO ACID SEQUENCE; ARTICLE; BLOOD CELL COUNT; BLOOD LEVEL; BODY MASS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE COUNT; FEMALE; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

AGED; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; GLUCOSE; HUMANS; INCIDENCE; LIPID METABOLISM; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 20244369731     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.205.327     Document Type: Article

References (31)

1. Alberti, K.G. & Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 15, 539-553.
2. Angles-Cano, E., de la Pena Diaz, A. & Loyau, S. (2001) Inhibition of fibrinolysis by lipoprotein(a). Ann. N. Y. Acad. Sci. 936, 261-275.
3. Boerwinkle, E. (1992) Genetics of plasma lipoprotein(a) concentrations. Curr. Opin. Lipldol., 3, 128-136.
4. Bonora, E. & Muggeo, M. (2001) Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia, 44, 2107-2114.
5. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A. & Leakso, M. (2002) STOP-NIDDM Trail Research Group. Acarbose for preventuon of type 2 diabetes mellitus. the STOP-NIDDM randomized trial. Lancet, 359, 2072-2077.
6. Cohen, M.P. & Clements, R.S. (1999) Measuring glycated proteins: clinical and methodological aspects. Diabetes Technol. Ther. 1, 57-70.
7. Creed, D.L., Baird, W.F. & Fisher, E.R. (1955) The severity of aortic arteriosclerosis in certain disease. A necropsy study. Am. J. Med. Sci., 230, 385-391.
8. DeFronzo, R.A. & Ferrannini, E. (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14, 173-194.
9. Eaton, D.L., Fless, G.M., Kohr, W.J., McLean, J.W., Xu, Q.T., Miller, C.G., Lawn, R.M. & Scanu, A.M. (1987) Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc. Natl. Acad. Sci. USA, 84, 3224-3228.
10. Garber, A.J. (2002) Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes. Metab., 4, Suppl. 1, 5-12.
11. Giampaolo, B., Giulio M., Zoli, M., Bugianesi,E., Fabbri, A. & Pisi, E. (1994) Prognostic Significance of Diabetes in Patients with Cirrhosis. Hepatology, 20, 119-125.
12. Grant, W.C., Wasserman, F. & Rodensky, P.L. (1949) The incidence of myocardial infarction in portal cirrosis. Ann. Int. Med. 31, 479-483.
13. Hanefeld, M., Fischer, S., Julius, U., Schwanebeck, U., Schmechel, H., Ziegelasch, H.J. & Lindner, J. (1996) Risk factors for myocardial infarction and death in newly detected NIDDM, The Diabetes Intervention Study, 11-year follow-up. Diabetologia, 39, 1577-1583.
14. Hernandez, C., Simo, R., Chacon, P., Segarra, A., Lopez, D. & Mesa, J. (1997) Relationship between lipoprotein(a) phenotypes and albumin excretion rate in non-insulin-dependent diabetes mellitus: protective effect of 'null' phenotype? Eur. J. Clin. Invest., 27 497-502.
15. Kuzuya, T., Nakagawa, S., Satoh, J., Kanazawa, Y., Iwamoto, Y., Kobayashi, M., Nanjo, K., Sasaki, A., Seino, Y., Ito, C., Shima, K., Nohaka, K. & Kadowaki, T. (2002) Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res. Clin. Pract., 55, 65-85.
16. Makino, Y. (1987) Lp(a) lipoprotein in type II diabetes mellitus, Studies on Lp(a) lipoprotein and vascular complications. Bulletin of the Gifu University School of Medicine, 35, 111-128.
17. Malaguarnera, M., Giugno, I., Trovato, B.A., Panebianco, M.P., Restuccia, N. & Ruello, P. (1996) Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr. Med. Res. Opin., 13, 479-485.
18. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
19. Marchesini, G., Ronchi, M., Forlani, G., Bugianesi, E., Bianchi, G., Fabbri, A., Zoli, M. & Melchionda, N. (1999) Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance. Am. J. Gastroenterol., 94, 655-662.
20. McLean, J.W., Tomlinson, J.E., Kuang, W.-J., Eaton, D.L., Chen, E.Y., Fless, G.M., Scanu, A.M. & Lawn, R.M. (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature, 330, 132-137.
21. Miyata, M., Biro, S., Kaieda, H. & Tanaka, H. (1995) Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett., 377, 493-496.
22. Murai, A., Miyahara, T., Fujimoto, N., Matsuda, M. & Kameyama, M. (1986) Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis, 59, 199-204.
23. Murakami, K., Ishibashi, S., Yoshida, Y., Yamada, N. & Akanuma, Y. (1998) Lipoprotein(a) as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) diabetes mellitus. Relation with apolipoprotein(a) phenotypes. Diabetologia, 41, 1397-1398.
24. Nomura, Y., Nanjo, K., Miyano, M., Kikuoka, H., Kuriyama, S., Maeda, M. & Miyamura, K. (1986) Hemoglobin A1 in cirrhosis of the liver. Diabetes Res., 11, 177-180.
25. Petrides, A.S. & DeFronzo, R.A. (1989) Glucose and insulin metabolism in cirrhosis. J. Hepatol., 8, 107-114.
26. Rhoads, G.G., Dahlen, G., Berg, K., Morton, N.E. & Dannenberg, A.L. (1986) Lp(a) lipoprotein as a risk factor for myocardial infection. JAMA, 256, 2540-2544.
27. Ricciardi, R., D'Ambrosio, F.P., Ricciardi, L., Romano, C. & Restuccia G. (1994) Lp(a) levels and reduced risk of vascular atheromatosis in patients with alcoholic liver disease. Riv. Eur. Sci. Med. Farmacol., 16, 119-123.
28. Skyler, J.S. (1996) Diabetic complications. The importance of glucose control. Endocrinol. Metab. Clin. North. Am., 25, 243-254.
29. Sotaniemi, E.A. & Keinanen, K. (1985) Carbohydrate intolerance associated with reduced hepatic glucose phosphorylating and releasing enzyme activities and peripheral insulin resistance in alcoholic with liver cirrosis. J. Hepatol., 1, 277-290.
30. Suehiro, M., Ohkubo, K., Kato, H., Kido, Y., Anzai, K., Oshima, K. & Ono, J. (2002) Analyses of serum lipoprotein(a) and the relation to phenotypes and genotypes of apolipoprotein(a) in type 2 diabetic patients with retinopathy. Exp. Clin. Endocrinol. Diabetes , 110, 319-324.
31. WHO Study Group. (1995) Diabetes mellitus, Tech. Rep. Ser. 727, WHO, Geneva, 29-31.